Fujitsu Embarks on Joint Research with National Cancer Center Japan


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
The joint research is aimed to create new services for drug development and clinical trials

Fujitsu today announced it has concluded a comprehensive collaborative research agreement with National Cancer Center Japan. The joint research will centre on exploring ways that real-world data, including medical information from electronic records, can be leveraged to contribute to the development of new drugs, clinical trials, and preventive medicine in pharmaceutical companies.

Through its joint research with the National Cancer Center, Fujitsu aims to create new value through a wide range of information and analysis services by creating an anonymized personal health record scheme (PHR), which includes case study information and health information on patients visiting the National Cancer Center Hospital East.

Fujitsu additionally seeks to create a platform for providing pharmaceutical companies with data that can be used for drug development and preventive medicine. Fujitsu will establish a new model to process medical information from electronic medical records into highly secure statistical data to improve the efficiency of clinical trials and supports active participation in international joint clinical trials by promoting the adaptation of clinical trial data in Japan to global standards.

With an eye to contributing to the wellbeing of people in society, Fujitsu will work to improve the development speed and quality of pharmaceuticals and other products that promote the health of consumers. In turn, Fujitsu will play a role in resolving issues such as the time required for clinical trials and costs, create a variety of services that contribute to areas such as preventive medicine and individualized cancer medicine, and implement these services by the end of fiscal 2021.

Background

In recent years, real-world data has been attracting increased attention in the healthcare field, and it is beginning to be used in a wide range of fields globally--from drug approval applications to the development of medical devices and preventive medicine. A variety of different data types are being used to these ends, ranging from patient electronic medical record information and medical examination information to daily measurement data such as weight and body composition monitors(4), as well as vital information such as temperature and blood pressure that can be obtained from smart devices.

Despite the potential for such data, however, challenges remain around extracting useful information from unstructured sources like doctors' notes, etc., and it has become necessary to develop new platforms and data extraction technologies to effectively and securely streamline the use of valuable medical data. To this end, Fujitsu has concluded a comprehensive agreement with the National Cancer Center with the ultimate goal of contributing to the speedy development of pharmaceuticals and clinical trials by pharmaceutical companies that promote the health of consumers and will start joint research in this field.

About the Joint Research
In collaboration with the National Cancer Center, Fujitsu is implementing three projects to utilize real-world data at the National Cancer Center Hospital East.

Verification of utilization of real-world data (real-world data share)
- In addition to medical information from the electronic medical record systems, which has been difficult to use until now, information on case studies and information on the health of local patients (PHR) is processed into a format that is easy for pharmaceutical companies to handle and provided as secure, high-quality data. The effectiveness of using real-world data in developing new AI technologies to support diagnoses and treatment will also be verified.

Establishment and validation of new clinical trial service models (DX for Clinical Trial Operations)
- Natural language analysis technology will be applied to the analysis of medical information in the electronic medical record system in order to establish a new clinical trial service model that can automatically identify appropriate clinical trial patients with overwhelming speed and accuracy. This process is presently performed manually with reference to medical information in the electronic medical record system (clinical trial patient recruitment). Through this study, the effectiveness of the system is significantly reducing the cost and duration of clinical trials, including improving the efficiency of in-hospital operations will be verified.
- Fujitsu will promote efforts to adapt clinical trial data in Japan to global standards and support active participation in international clinical trials.

Establishment of a platform for safe and secure use of medical data (common platform)
- In order to carry out these two verifications, Fujitsu will develop a platform that can safely and securely utilize medical data by converting medical information recorded as text data in the electronic medical record system into a format that can be utilized as data. This platform utilizes technology developed by Fujitsu Laboratories, Ltd., as well as data extraction technology that is being newly developed.

Tags : #Fujitsu #JointResearch #JapanCancerCentre #ClinicalTrials #DrugDelivery #PharmaNews #LatestPharmaNews

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026